Relationship between plasma progesterone, estradiol and prolactin concentrations and breast cancer in pre and postmenopausal women

Neoplasma

Volumn 57, Issue 1, 2010, Pages 74-78

  Raheem, S N A ^a   Atoum, M ^a   Al Hourani, H ^a   Rasheed, M ^a   Nimer, N ^a   Almuhrib, T ^a  

^a HASHEMITE UNIVERSITY   (Jordan)

Author keywords

Breast cancer; Plasma hormones; Premenopausal and postmenopausal

Indexed keywords

ESTRADIOL; PROGESTERONE; PROLACTIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER CENTER; CANCER GROWTH; CANCER PATIENT; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREMENOPAUSE; PROGESTERONE BLOOD LEVEL; PROLACTIN BLOOD LEVEL; ADOLESCENT; BLOOD; BREAST TUMOR; MENOPAUSE; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; ESTRADIOL; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; PROGESTERONE; PROLACTIN;

EID: 77953622928     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2010_01_074     Document Type: Article

References (34)

1. GELMON K, CHERMAINE KS. Hormonal therapy and breast cancer. BCMJ 2001;43: 511-6.
2. BRODY J, RUDEL RA. Environmental pollutants and breast cancer. Environmental Health Perspectives 2003; 111: 1007-1019.
3. TRAVIS RC, KEY, TJ. Estrogen exposure and breast cancer risk. Breast Cancer Res 2003; 5: 239-247. doi:10.1186/bcr628
4. TONIOLO PG, LEUTIZ M. A prospective study of endogenous estrogens and breast cancer in post menopause women. Journal of the National Cancer Institute 1995; 87: 190-197. doi:10.1093/jnci/87.3.190
5. DORGAN JF. Endogenous sex hormones and breast cancer in postmenopausal women: a reanalysis of high prospective studies. Journal of the National Cancer Institute 2002; 94: 606-616.
6. HANKINSON SE, WILLETTE WC, MICHAUD DS, MANSON JE, COLDITZ GA. et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. Journal of the National Cancer Institute 1999; 91: 692-634. doi:10.1093/jnci/91.7.629
7. TWOROGER SS, ELIASSEN AH, RONSNER B, SLUSS P. Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 2004; 64: 6814-9. doi:10.1158/0008-5472. CAN-04-1870
8. TWOROGER SS, ELIASSEN AH, SLUSS P, HANKINSON SE. A prospective study of plasma prolactin concentrations and the risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 2007; 25: 1482-8. doi:10.1200/ JCO.2006.07.6356
9. CLEVENGER V, CHANG W-P, NGO W, PASHA TLM, MONTONE KT. et al Expression of prolactin and prolactin receptor in human breast carcinoma evidence for an autocrine /paracrine loop, Am J Pathol 1995; 146: 695-705.
10. CLEVENGER CV, FURTH PA, HANKINSON SE, SCULER LA. The role of prolactin in mammary carcinoma, Endocrine Reviews 2003; 24: 1-27, doi:10.1210/er.2001-0036
11. WANG DY, DE STAVOLA BL, BULBROOK RD, ALLEN DS, KWA HG et al. Relationship of blood prolactin levels and the risk of subsequented breast cancer. Int J Epidemiol 1992; 21: 214-21. doi:10.1093/ije/21.2.214
12. TWOROGER SS, HANKINSON SE. Prolactin and breast cancer risk. Cancer Lett 2006; 243: 160-9. doi:10.1016/ j.canlet.2006.01.032
13. BOOMSMA D, PAOLETTI J. A review of current research on the effects of progesterone, International Journal of Pharmaceutical Compounding 2002; 6: 245-249.
14. JATOI I, CHEN BE, ANDERSON WF, ROSENBERG PS. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol 2007; 25: 1689-90. doi:10.1200/JCO.2006.09.2106
15. LYDON JP, SIVARAMAN L, CONNEELY OM. A reappraisal of progesterone action in the mammary gland. J Mammary Gland Biol Neoplasia 2000; 5: 325-338. doi:10.1023/A:1009555013246
16. ROSS RK, PAGANINI-HILL A, WAN PC, PIKE MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. Journal of the National Cancer Institute 2002; 92: 328-332. doi:10.1093/jnci/92.4.328
17. SITRUK-WARE R. Progestegen in hormonal replacement therapy new molecules, risks and benefits. Menopause: J North Am Menopause Soc 2002; 9: 6-15.
18. JOSHI UM, SHAH HP, SUDHAMA SP. A sensitive and specific enzyme immunoassay for serum testosterone, Steroids 1979; 34: 35-46 doi:10.1016/0039-128X(79)90124-7
19. Tietz, NW. ed, 1995 Clinical Guide to Laboratory Tests, 3rd edition, W.B. Sannders, Co. Philadelphia, 509-512.
20. SEPPALA M. Prolactin and female reproduction. Ann Clin Res 1978;10: 164-170.
21. KEY TJ, PIKE MC. The role of estrogens and progestins in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 1988; 24: 29-43. doi:10.1016/0277-5379(88)90173-3
22. GAPSTUR SM, MORROW M, SELLERS T. Hormone replacement therapy and risk of breast cancer with favorable histology. JAMA 1999; 281: 2091-2097. doi:10.1001/ jama.281.22.2091
23. CAMPAGNOLI C, CLAVEL-CHAPELON F, KAAKS R, PERIS C, BERRINO F. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol 2005; 96: 95-108. doi:10.1016/ j.jsbmb.2005.02.014
24. KEY TJ, APPLEBY PN, REEVES GK, RODDAM A, DORGAN JF. et al. Body mass index, serum sex hormones and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003; 95: 1218-1226.
25. LEE SA, HAIMAN CA, BURTT NP, POOLER LC, CHENG I et al. A comprehensive analysis of common genetic variation in prolactin (PRL) and PRL receptor (PRLR) genes in relation to plasma prolactin levels and breast cancer risk: the multiethnic cohort. 2007; 8: 72.
26. GOODMAN G., BERCOVICH D. Prolactin does not cause breast cancer and may prevent it or be therapeutic in some conditions. Med Hypotheses 2008; 70: 244-51. doi:10.1016/ j.mehy.2007.05.027
27. FIELDS K, KULIG E, LLOYD RV. Detection of prolactin messenger RNA in mammary and other normal and neoplastic tissues by polymerase chain reaction. Lab Invest 1993; 68: 354-60.
28. GINSBURG E, VONDERHAAR BK. Prolactin synthesis and secretion by human breast cells, Cancer Res 1995; 55: 2591-5.
29. CALAF G, GARRIDO F, MOYANNO C, RODRIGUES R. Influence of hormones on DNA synthesis of breast tumors in culture. Breast Cancer Res Treat 1986; 8: 223-32. doi:10.1007/ BF01807335
30. BEEBY DI, EASTY GC, GAZET JC, GRIOGR K, NEVILLE AM. An assessment of the effects of hormones on short term organ cultures of human breast carcinomata, Br J Cancer 1975;. 31: 317-28.
31. ROSE DP, PRUITT BT. Plasma prolactin levels in patients with breast cancer. Cancer 1981; 48: 2687-91. doi:10.1002/1097-014 2(19811215)48:12<2687::AID-CNCR2820481221>3.0.CO;2-A
32. INGRAM DM, NOTTAGE EM, ROBERTS AN. Prolactin and breast cancer risk, Med J Aust 1990; 153: 469-73.
33. MALARKEY WB, SCHROEDER LL, STEVENS VC, JAMES AG, LANESE RR. Disordered nocturnal prolactin regulation in women with breast cancer. Cancer Res 1977; 37: 4650-4.
34. BERNSTEIN L, ROSE RK, PIKE MC, BROWN JB, HENDERSON BE. Hormone levels in older women; a study of post menopausal breast cancer patients and healthy population controls. Br J Cancer 1990; 61: 298-302.